Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD)
Overview
Reductions in exercise capacity associated with exercise intolerance augment cardiovascular disease risk and predict mortality in chronic kidney disease. This study utilized cardiopulmonary exercise testing to (a) investigate mechanisms of exercise intolerance; (b) unmask subclinical ca and p and vitamin D abnormalities that may precede cardiovascular disease in chronic kidney disease.
Full Title of Study: “Evaluation of the Relationship Between Cardiopulmonary Exercise Testing (CPET ) Abnormalities and Ca-P Status in CKD Stage3-5”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: August 1, 2021
Detailed Description
Cardiopulmonary exercise testing will carry out in Stage 3-5 chronic kidney disease patients ; estimated glomerular filtration rate <60 ml/min/1.73 m2) and biochemistry will be added (Ca P Via D PTH FGF23).
Interventions
- Diagnostic Test: CPET
- CPET
Arms, Groups and Cohorts
- CKD Stage 3
- CKD patients with GFR between 30-60cc/min
- CKD Stage 4
- CKD Patients with GFR 15-30 cc/min
Clinical Trial Outcome Measures
Primary Measures
- Calcium x phosphorus change in stage 3-5
- Time Frame: 12 MONTHS
- CaxP change
- CPET score change
- Time Frame: 12 MONTHS
- Evaluation of CPET score change
Secondary Measures
- Renal Function change
- Time Frame: 12 MONTHS
- GFR change
Participating in This Clinical Trial
Inclusion Criteria
- CKD Patients with GFR <60 non-dialysis – age<18 Exclusion Criteria:
- HTN – not signing consent – active coronary disease
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Provider of Information About this Clinical Study
- Principal Investigator: nooshin dalili, Principal Investigator – Shahid Beheshti University of Medical Sciences
- Overall Official(s)
- Dalili, Principal Investigator, SBMU
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.